Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 71.51%
March 31, 2026 71.98%
December 31, 2025 70.49%
September 30, 2025 75.59%
June 30, 2025 75.65%
March 31, 2025 75.13%
December 31, 2024 76.93%
September 30, 2024 73.43%
June 30, 2024 73.43%
March 31, 2024 75.11%
December 31, 2023 69.77%
September 30, 2023 70.74%
June 30, 2023 70.67%
March 31, 2023 70.21%
December 31, 2022 69.22%
September 30, 2022 74.50%
June 30, 2022 71.97%
March 31, 2022 66.60%
December 31, 2021 72.55%
September 30, 2021 74.06%
June 30, 2021 72.97%
March 31, 2021 69.84%
December 31, 2020 54.29%
September 30, 2020 72.70%
June 30, 2020 70.78%
Date Value
March 31, 2020 72.98%
December 31, 2019 69.70%
September 30, 2019 68.11%
June 30, 2019 71.44%
March 31, 2019 72.01%
December 31, 2018 70.17%
September 30, 2018 66.51%
June 30, 2018 66.99%
March 31, 2018 68.65%
December 31, 2017 67.80%
September 30, 2017 68.17%
June 30, 2017 68.79%
March 31, 2017 69.21%
December 31, 2016 67.18%
September 30, 2016 67.85%
June 30, 2016 65.06%
March 31, 2016 64.30%
December 31, 2015 62.71%
September 30, 2015 62.73%
June 30, 2015 62.00%
March 31, 2015 62.71%
December 31, 2014 60.71%
September 30, 2014 75.06%
June 30, 2014 62.84%
March 31, 2014 63.14%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Johnson & Johnson 68.73%
Eli Lilly & Co. 85.78%
Pfizer Inc. 62.94%
Bristol Myers Squibb Co. 67.95%
Viatris, Inc. 41.92%